Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting.

CSTD Closed System Drug Transfer Device MAB clinical trials guideline health and safety monoclonal antibodies safe handling

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 30 11 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: ppublish

Résumé

Available guidelines are ambiguous about safe handling monoclonal antibodies (MABs) and whether or not to use a Closed System Drug-Transfer Device (CSTD). In this article we want to describe a standardized working method on handling MABs in a clinical trial setting. The current workflow at the clinical trial unit of the Ghent University Hospital was critically analyzed, after which an extensive literature review was performed using the National Institute for Occupational Safety and Health Working Group guidelines and the database PubMed (Keywords: monoclonal antibodies, closed system transfer devices, safety guidelines, safe handling, management, administration, (bio)compatibility, volume loss, contamination, clinical trial unit. Period: 2020-2022). Literature data are ambiguous. CSTDs can reduce cross-contamination and minimize exposure to potential hazardous drugs for healthcare professionals. However, in recent years more questions have been raised about their in-use compatibility and their impact on final product quality. This makes the debate on implementing CSTDs a hot topic in daily pharmacy practice and demands a holistic and standardized approach when deciding whether or not to use a CSTD when handling MABs. In a clinical trial setting, where safety data are frequently not available and the compatibility of CSTDs and investigational product is often unknown, this poses additional challenges that need to be taken into account. We developed a flowchart which standardizes the use of a CSTD when handling MABs. It allows other healthcare professionals and clinical trial sponsors to define and evaluate the necessary criteria when standardizing the position of a CSTD in their safe handling procedures.

Identifiants

pubmed: 37680124
doi: 10.1177/10781552231199412
doi:

Substances chimiques

Pharmaceutical Preparations 0
Antibodies, Monoclonal 0
Antineoplastic Agents 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2014-2022

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Ine Simal (I)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Tiene Bauters (T)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Charline Paepens (C)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Nele Clottens (N)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Pieter Ramaut (P)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Els Kestens (E)

Pharmacy Department, Ghent University Hospital, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH